EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2025: Significant increase in net sales and earnings – upper half of forecast range expected

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2025: Significant increase in net sales and earnings – upper half of forecast range expected

Lübeck, October 15, 2025 – Based on preliminary calculations, Dräger increased its net sales in the third quarter of 2025 by 10.1 percent (net of currency effects; nominal: 7.6 percent) to around EUR 833 million (Q3 2024: EUR 774.6 million). Both divisions recorded significant growth again after a decline in the prior year. The medical division saw an increase of 10.2 percent (net of currency effects; nominal: 7.3 percent) to around EUR 471 million (Q3 2024: EUR 439.1 million), while the safety division grew by 9.9 percent (net of currency effects; nominal: 7.9 percent) to around EUR 362 million (Q3 2024: EUR 335.5 million). The Group's gross margin rose to around 45.6 percent (Q3 2024: 43.5 percent).

Earnings before interest and taxes (EBIT) increased to around EUR 57 million, more than doubling (Q3 2024: EUR 24.4 million). In the same quarter of the prior year, EBIT had been still supported by a positive one-off effect amounting to around EUR 10 million. The main reason for the good earnings performance in the third quarter of 2025 was the significant growth in net sales, while costs rose only moderately. The EBIT margin improved by 3.7 percentage points to 6.8 percent (Q3 2024: 3.1 percent).

Order intake rose by 6.9 percent in the third quarter (net of currency effects; nominal: 4.9 percent) to around EUR 856 million (Q3 2024: EUR 816.2 million). In the medical division, it increased by 5.4 percent (net of currency effects; nominal: 3.5 percent) to around EUR 485 million (Q3 2024: EUR 468.4 million) following a decline in the prior year. In the safety division, order intake grew by 8.8 percent (net of currency effects; nominal: 6.8 percent) to around EUR 371 million (Q3 2024: EUR 347.8 million).

Business performance in the first nine months of 2025
Order intake rose by 9.0 percent (net of currency effects; nominal: 7.2 percent) to around EUR 2,594 million in the first nine months. This not only exceeded the prior year's high level (9 months 2024: EUR 2,420.5 million), but also reached the highest nine-month level since the record year of 2020. Both divisions contributed to this positive development: in the medical division, order intake increased significantly by 11.6 percent (net of currency effects; nominal: 9.3 percent) after a decline in the prior year to around EUR 1,496 million (9 months 2024: EUR 1,368.5 million); this was partly due to a major multi-year order from Mexico in the mid double-digit million euro range, which Dräger received in the second quarter. In safety division, order intake in the first nine months rose by 5.7 percent (net of currency effects; nominal: 4.4 percent) to around EUR 1,099 million (9 months 2024: EUR 1,052.1 million).

Net sales increased by 3.7 percent (net of currency effects; nominal: 2.1 percent) to around EUR 2,344 million (9 months 2024: EUR 2,295.1 million). Following a decline in the prior year, the medical division recorded growth of 4.7 percent (net of currency effects; nominal: 2.9 percent) to around EUR 1,322 million (9 months 2024: EUR 1,285.3 million). The safety division grew by 2.4 percent (net of currency effects; nominal: 1.1 percent) to around EUR 1,021 million (9 months 2024: EUR 1,009.7 million). The Group's gross margin rose to around 45.1 percent (9 months 2024: 44.4 percent).

At around EUR 77 million, EBIT did not reach the prior year's figure (9 months 2024: EUR 80.1 million), but this was mainly due to the positive one-off effects in the prior year: In the second quarter of 2024, Dräger sold a non-strategic business area in the Netherlands and a property in the U.S. for a total of around EUR 20 million in addition to the sale of a building in Spain for around EUR 10 million in the third quarter of 2024. These earnings contributions are now missing. Currency effects and customs duties also had a negative impact on earnings in the first nine months of 2025. The EBIT margin amounted to around 3.3 percent (9 months 2024: 3.5 percent).

Forecast for 2025: Net sales and EBIT margin expected to be rather in the upper half of the range
Due to the very good business performance and the continued high order intake, we now tend to expect net sales growth of 3.0 to 5.0 percent net of currency effects (previously 1.0 to 5.0 percent net of currency effects) and an EBIT margin of 4.5 to 6.5 percent (previously 3.5 to 6.5 percent).

The full results for the first nine months of the fiscal year will be published on October 29, 2025.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
melanie.kamann@draeger.com

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.